Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hassel

Showing results (191-200 of 271) with videos related to

Pageof 28
Sort By:
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell ClonesIsabel C Poschke, Jessica C Hassel, Aaron Rodriguez-Ehrenfried, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIvelina Spassova, Selma Ugurel, Linda Kubat, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
Pageof 28

Showing results (191-200 of 271) with videos related to

Sort By:
Pageof 28
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell ClonesIsabel C Poschke, Jessica C Hassel, Aaron Rodriguez-Ehrenfried, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIvelina Spassova, Selma Ugurel, Linda Kubat, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
Pageof 28